Login    Join free Add to favorites    中文
Home > News > AMSBIO: Engineering Immune Cells to Treat Cancers
Industry Updates New Products Supplier News Upcoming Events business web
AMSBIO: Engineering Immune Cells to Treat Cancers
hits:669     Date:08/24/18

AMSBIO produce a growing range of experimental cell lines, recombinant proteins and screening services to advance the search for new Chimeric Antigen Receptor (CAR T) cell therapies to treat cancers.

For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last twenty years, therapeutic drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells, have also become standard treatments for many cancers. In the last few years - immunotherapies that enlist and strengthen the power of a patient鈥檚 immune system to attack tumors have emerged as a new and very promising cancer treatment.

Until recently, the use of CAR T-cell immunotherapy has been restricted to small clinical trials, largely in patients with advanced blood cancers. However, these treatments have created great interest because of the remarkable responses they have produced in some children and adults for whom all other treatments had stopped working. In 2017, two CAR T-cell therapies were approved by the Food and Drug Administration (FDA), one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas. 

A therapeutic CAR is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain, along with other costimulatory receptors. The scFv provides a specific binding domain that recognizes target proteins on cancer cells. A patient鈥檚 own T cells are isolated and activated, then transfected with a gene expressing the CAR. This reprograms the T cells to identify and attack tumor cells expressing the target protein, creating personalized immune cells designed to specifically target the patient鈥檚 cancer.

For further information on AMSBIO's growing range of experimental cell lines, recombinant proteins and screening services to help develop new CAR T cell therapies please visit http://www.amsbio.com/car-t-cell-research.aspx or contact the company on +44-1235-828200/ +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
North American HQ
1035 Cambridge Street
MA 02141
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com    
Web www.amsbio.com
Related News>> more
Copyright(C) 2006-2019 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙